Search

Your search keyword '"O'Driscoll, Lorraine"' showing total 524 results
Start Over Author "O'Driscoll, Lorraine"
524 results on '"O'Driscoll, Lorraine"'

2. Unravelling the biological and clinical challenges of circulating tumour cells in epithelial ovarian carcinoma

Author

Lewis, Faye, Beirne, James, Henderson, Brian, Norris, Lucy, Cadoo, Karen, Kelly, Tanya, Martin, Cara, Hurley, Sinéad, Kanjuga, Marika, O'Driscoll, Lorraine, Gately, Kathy, Oner, Ezgi, Saini, Volga M., Brooks, Doug, Selemidis, Stavros, Kamran, Waseem, Haughey, Niamh, Maguire, Patrick, O'Gorman, Catherine, Saadeh, Feras Abu, Ward, Mark P., O'Leary, John J., and O'Toole, Sharon A.

Published
2024
Full Text
View/download PDF

6. International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19

Author

Börger, Verena, Weiss, Daniel J, Anderson, Johnathon D, Borràs, Francesc E, Bussolati, Benedetta, Carter, David RF, Dominici, Massimo, Falcón-Pérez, Juan M, Gimona, Mario, Hill, Andrew F, Hoffman, Andrew M, de Kleijn, Dominique, Levine, Bruce L, Lim, Rebecca, Lötvall, Jan, Mitsialis, S Alex, Monguió-Tortajada, Marta, Muraca, Maurizio, Nieuwland, Rienk, Nowocin, Anna, O'Driscoll, Lorraine, Ortiz, Luis A, Phinney, Donald G, Reischl, Ilona, Rohde, Eva, Sanzenbacher, Ralf, Théry, Clotilde, Toh, Wei Seong, Witwer, Kenneth W, Lim, Sai Kiang, and Giebel, Bernd

Subjects
Medical Biotechnology, Biomedical and Clinical Sciences, Regenerative Medicine, 5.2 Cellular and gene therapies, Development of treatments and therapeutic interventions, Generic health relevance, Good Health and Well Being, Coronavirus Infections, Exosomes, Extracellular Vesicles, Humans, Mesenchymal Stem Cells, Societies, Scientific, COVID-19 Drug Treatment, Clinical Sciences, Immunology, Medical biotechnology
Abstract

StatementThe International Society for Cellular and Gene Therapies (ISCT) and the International Society for Extracellular Vesicles (ISEV) recognize the potential of extracellular vesicles (EVs, including exosomes) from mesenchymal stromal cells (MSCs) and possibly other cell sources as treatments for COVID-19. Research and trials in this area are encouraged. However, ISEV and ISCT do not currently endorse the use of EVs or exosomes for any purpose in COVID-19, including but not limited to reducing cytokine storm, exerting regenerative effects or delivering drugs, pending the generation of appropriate manufacturing and quality control provisions, pre-clinical safety and efficacy data, rational clinical trial design and proper regulatory oversight.

Published
2020

8. Prospective evaluation of the breast microbiome and tumor microenvironment-related biomarkers of response to neoadjuvant systemic therapy in triple negative breast cancer.

Author

Hennessy, Maeve, primary, Morais, Emilene S, additional, Devoy, Ciaran, additional, Walsh, Grace, additional, Crowley, Erin, additional, Lynch, Emer, additional, Twomey, Maria, additional, Girleanu, Corina, additional, Dahly, Darren L, additional, O'Driscoll, Lorraine, additional, Foley, Cathriona, additional, Bennett, Michael William, additional, O'Hanlon, Deirdre, additional, Tangney, Mark, additional, and Connolly, Roisin M., additional

Published
2024
Full Text
View/download PDF

10. Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.

Author

Eustace, Alex J, Conlon, Neil T, McDermott, Martina SJ, Browne, Brigid C, O'Leary, Patrick, Holmes, Frankie A, Espina, Virginia, Liotta, Lance A, O'Shaughnessy, Joyce, Gallagher, Clair, O'Driscoll, Lorraine, Rani, Sweta, Madden, Stephen F, O'Brien, Neil A, Ginther, Charles, Slamon, Dennis, Walsh, Naomi, Gallagher, William M, Zagozdzon, Radoslaw, Watson, William R, O'Donovan, Norma, and Crown, John

Subjects
Cell Line, Tumor, Humans, Breast Neoplasms, Proto-Oncogene Proteins c-bcl-2, Antineoplastic Agents, Apoptosis, Gene Expression, Phosphorylation, Drug Resistance, Neoplasm, Genes, erbB-2, Female, CASP8 and FADD-Like Apoptosis Regulating Protein, TNF-Related Apoptosis-Inducing Ligand, Forkhead Box Protein O3, Lapatinib, AKT, ErbB2, FOXO3a, MCL-1, cFLIP, Cancer, Breast Cancer, Development of treatments and therapeutic interventions, 2.1 Biological and endogenous factors, 5.1 Pharmaceuticals, Aetiology, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundLapatinib has clinical efficacy in the treatment of trastuzumab-refractory HER2-positive breast cancer. However, a significant proportion of patients develop progressive disease due to acquired resistance to the drug. Induction of apoptotic cell death is a key mechanism of action of lapatinib in HER2-positive breast cancer cells.MethodsWe examined alterations in regulation of the intrinsic and extrinsic apoptosis pathways in cell line models of acquired lapatinib resistance both in vitro and in patient samples from the NCT01485926 clinical trial, and investigated potential strategies to exploit alterations in apoptosis signalling to overcome lapatinib resistance in HER2-positive breast cancer.ResultsIn this study, we examined two cell lines models of acquired lapatinib resistance (SKBR3-L and HCC1954-L) and showed that lapatinib does not induce apoptosis in these cells. We identified alterations in members of the BCL-2 family of proteins, in particular MCL-1 and BAX, which may play a role in resistance to lapatinib. We tested the therapeutic inhibitor obatoclax, which targets MCL-1. Both SKBR3-L and HCC1954-L cells showed greater sensitivity to obatoclax-induced apoptosis than parental cells. Interestingly, we also found that the development of acquired resistance to lapatinib resulted in acquired sensitivity to TRAIL in SKBR3-L cells. Sensitivity to TRAIL in the SKBR3-L cells was associated with reduced phosphorylation of AKT, increased expression of FOXO3a and decreased expression of c-FLIP. In SKBR3-L cells, TRAIL treatment caused activation of caspase 8, caspase 9 and caspase 3/7. In a second resistant model, HCC1954-L cells, p-AKT levels were not decreased and these cells did not show enhanced sensitivity to TRAIL. Furthermore, combining obatoclax with TRAIL improved response in SKBR3-L cells but not in HCC1954-L cells.ConclusionsOur findings highlight the possibility of targeting altered apoptotic signalling to overcome acquired lapatinib resistance, and identify potential novel treatment strategies, with potential biomarkers, for HER2-positive breast cancer that is resistant to HER2 targeted therapies.

Published
2018

13. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

Author

Welsh, Joshua A., Goberdhan, Deborah C. I., O’Driscoll, Lorraine, Buzas, Edit I., Blenkiron, Cherie, Bussolati, Benedetta, Cai, Houjian, Di Vizio, Dolores, Driedonks, Tom A. P., Erdbrügger, Uta, Falcon-Perez, Juan M., Fu, Qing-Ling, Hill, Andrew F., Lenassi, Metka, Lim, Sai Kiang, M˜y, G. Mahoney, Mohanty, Sujata, Möller, Andreas, Nieuwland, Rienk, Ochiya, Takahiro, Sahoo, Susmita, Torrecilhas, Ana C., Zheng, Lei, Zijlstra, Andries, Abuelreich, Sarah, Bagabas, Reem, Bergese, Paolo, Bridges, Esther M., Brucale, Marco, Burger, Dylan, Carney, Randy P., Cocucci, Emanuele, Crescitelli, Rossella, Hanser, Edveena, Harris, Adrian L., Haughey, Norman J., Hendrix, An, Ivanov, Alexander R., Jovanovic-Talisman, Tijana, Kruh-Garcia, Nicole A., Faustino, Vroniqa Ku’ulei-Lyn, Kyburz, Diego, Lässer, Cecilia, Lennon, Kathleen M., Lötvall, Jan, Maddox, Adam L., Martens-Uzunova, Elena S., Mizenko, Rachel R., Newman, Lauren A., Ridolfi, Andrea, Rohde, Eva, Rojalin, Tatu, Rowland, Andrew, Saftics, Andras, Sandau, Ursula S., Saugstad, Julie A., Shekari, Faezeh, Swift, Simon, Ter-Ovanesyan, Dmitry, Tosar, Juan P., Useckaite, Zivile, Valle, Francesco, Varga, Zoltan, van der Pol, Edwin, van Herwijnen, Martijn J. C., Wauben, Marca H. M., Wehman, Ann M., Williams, Sarah, Zendrini, Andrea, Zimmerman, Alan J., MISEV Consortium, Thery, Clotilde, Witwer, Kenneth W., Welsh, Joshua A., Goberdhan, Deborah C. I., O’Driscoll, Lorraine, Buzas, Edit I., Blenkiron, Cherie, Bussolati, Benedetta, Cai, Houjian, Di Vizio, Dolores, Driedonks, Tom A. P., Erdbrügger, Uta, Falcon-Perez, Juan M., Fu, Qing-Ling, Hill, Andrew F., Lenassi, Metka, Lim, Sai Kiang, M˜y, G. Mahoney, Mohanty, Sujata, Möller, Andreas, Nieuwland, Rienk, Ochiya, Takahiro, Sahoo, Susmita, Torrecilhas, Ana C., Zheng, Lei, Zijlstra, Andries, Abuelreich, Sarah, Bagabas, Reem, Bergese, Paolo, Bridges, Esther M., Brucale, Marco, Burger, Dylan, Carney, Randy P., Cocucci, Emanuele, Crescitelli, Rossella, Hanser, Edveena, Harris, Adrian L., Haughey, Norman J., Hendrix, An, Ivanov, Alexander R., Jovanovic-Talisman, Tijana, Kruh-Garcia, Nicole A., Faustino, Vroniqa Ku’ulei-Lyn, Kyburz, Diego, Lässer, Cecilia, Lennon, Kathleen M., Lötvall, Jan, Maddox, Adam L., Martens-Uzunova, Elena S., Mizenko, Rachel R., Newman, Lauren A., Ridolfi, Andrea, Rohde, Eva, Rojalin, Tatu, Rowland, Andrew, Saftics, Andras, Sandau, Ursula S., Saugstad, Julie A., Shekari, Faezeh, Swift, Simon, Ter-Ovanesyan, Dmitry, Tosar, Juan P., Useckaite, Zivile, Valle, Francesco, Varga, Zoltan, van der Pol, Edwin, van Herwijnen, Martijn J. C., Wauben, Marca H. M., Wehman, Ann M., Williams, Sarah, Zendrini, Andrea, Zimmerman, Alan J., MISEV Consortium, Thery, Clotilde, and Witwer, Kenneth W.

Abstract

Extracellular vesicles (EVs), through their complex cargo, can reflect the state of their cell of origin and change the functions and phenotypes of other cells. These features indicate strong biomarker and therapeutic potential and have generated broad interest, as evidenced by the steady year-on-year increase in the numbers of scientific publications about EVs. Important advances have been made in EV metrology and in understanding and applying EV biology. However, hurdles remain to realising the potential of EVs in domains ranging from basic biology to clinical applications due to challenges in EV nomenclature, separation from non-vesicular extracellular particles, characterisation and functional studies. To address the challenges and opportunities in this rapidly evolving field, the International Society for Extracellular Vesicles (ISEV) updates its ‘Minimal Information for Studies of Extracellular Vesicles’, which was first published in 2014 and then in 2018 as MISEV2014 and MISEV2018, respectively. The goal of the current document, MISEV2023, is to provide researchers with an updated snapshot of available approaches and their advantages and limitations for production, separation and characterisation of EVs from multiple sources, including cell culture, body fluids and solid tissues. In addition to presenting the latest state of the art in basic principles of EV research, this document also covers advanced techniques and approaches that are currently expanding the boundaries of the field. MISEV2023 also includes new sections on EV release and uptake and a brief discussion of in vivo approaches to study EVs. Compiling feedback from ISEV expert task forces and more than 1000 researchers, this document conveys the current state of EV research to facilitate robust scientific discoveries and move the field forward even more rapidly., Godkänd;2024;Nivå 0;2024-04-05 (marisr);Full text license: CC BY

Published
2024
Full Text
View/download PDF

14. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

Author

Welsh, Joshua A, Goberdhan, Deborah C I, O'Driscoll, Lorraine, Buzas, Edit I, Blenkiron, Cherie, Bussolati, Benedetta, Cai, Houjian, Di Vizio, Dolores, Driedonks, Tom A P, Erdbrügger, Uta, Falcon-Perez, Juan M, Fu, Qing-Ling, Hill, Andrew F, Lenassi, Metka, Lim, Sai Kiang, Mahoney, Mỹ G, Mohanty, Sujata, Möller, Andreas, Nieuwland, Rienk, Ochiya, Takahiro, Sahoo, Susmita, Torrecilhas, Ana C, Zheng, Lei, Zijlstra, Andries, Abuelreich, Sarah, Bagabas, Reem, Bergese, Paolo, Bridges, Esther M, Brucale, Marco, Burger, Dylan, Carney, Randy P, Cocucci, Emanuele, Colombo, Federico, Crescitelli, Rossella, Hanser, Edveena, Harris, Adrian L, Haughey, Norman J, Hendrix, An, Ivanov, Alexander R, Jovanovic-Talisman, Tijana, Kruh-Garcia, Nicole A, Ku'ulei-Lyn Faustino, Vroniqa, Kyburz, Diego, Lässer, Cecilia, Lennon, Kathleen M, Lötvall, Jan, Maddox, Adam L, Martens-Uzunova, Elena S, Mizenko, Rachel R, Newman, Lauren A, Ridolfi, Andrea, Rohde, Eva, Rojalin, Tatu, Rowland, Andrew, Saftics, Andras, Sandau, Ursula S, Saugstad, Julie A, Shekari, Faezeh, Swift, Simon, Ter-Ovanesyan, Dmitry, Tosar, Juan P, Useckaite, Zivile, Valle, Francesco, Varga, Zoltan, van der Pol, Edwin, van Herwijnen, Martijn J C, Wauben, Marca H M, Wehman, Ann M, Williams, Sarah, Zendrini, Andrea, Zimmerman, Alan J, Misev Consortium, null, Théry, Clotilde, Witwer, Kenneth W, Stoorvogel, Willem, Welsh, Joshua A, Goberdhan, Deborah C I, O'Driscoll, Lorraine, Buzas, Edit I, Blenkiron, Cherie, Bussolati, Benedetta, Cai, Houjian, Di Vizio, Dolores, Driedonks, Tom A P, Erdbrügger, Uta, Falcon-Perez, Juan M, Fu, Qing-Ling, Hill, Andrew F, Lenassi, Metka, Lim, Sai Kiang, Mahoney, Mỹ G, Mohanty, Sujata, Möller, Andreas, Nieuwland, Rienk, Ochiya, Takahiro, Sahoo, Susmita, Torrecilhas, Ana C, Zheng, Lei, Zijlstra, Andries, Abuelreich, Sarah, Bagabas, Reem, Bergese, Paolo, Bridges, Esther M, Brucale, Marco, Burger, Dylan, Carney, Randy P, Cocucci, Emanuele, Colombo, Federico, Crescitelli, Rossella, Hanser, Edveena, Harris, Adrian L, Haughey, Norman J, Hendrix, An, Ivanov, Alexander R, Jovanovic-Talisman, Tijana, Kruh-Garcia, Nicole A, Ku'ulei-Lyn Faustino, Vroniqa, Kyburz, Diego, Lässer, Cecilia, Lennon, Kathleen M, Lötvall, Jan, Maddox, Adam L, Martens-Uzunova, Elena S, Mizenko, Rachel R, Newman, Lauren A, Ridolfi, Andrea, Rohde, Eva, Rojalin, Tatu, Rowland, Andrew, Saftics, Andras, Sandau, Ursula S, Saugstad, Julie A, Shekari, Faezeh, Swift, Simon, Ter-Ovanesyan, Dmitry, Tosar, Juan P, Useckaite, Zivile, Valle, Francesco, Varga, Zoltan, van der Pol, Edwin, van Herwijnen, Martijn J C, Wauben, Marca H M, Wehman, Ann M, Williams, Sarah, Zendrini, Andrea, Zimmerman, Alan J, Misev Consortium, null, Théry, Clotilde, Witwer, Kenneth W, and Stoorvogel, Willem

Abstract

Extracellular vesicles (EVs), through their complex cargo, can reflect the state of their cell of origin and change the functions and phenotypes of other cells. These features indicate strong biomarker and therapeutic potential and have generated broad interest, as evidenced by the steady year-on-year increase in the numbers of scientific publications about EVs. Important advances have been made in EV metrology and in understanding and applying EV biology. However, hurdles remain to realising the potential of EVs in domains ranging from basic biology to clinical applications due to challenges in EV nomenclature, separation from non-vesicular extracellular particles, characterisation and functional studies. To address the challenges and opportunities in this rapidly evolving field, the International Society for Extracellular Vesicles (ISEV) updates its 'Minimal Information for Studies of Extracellular Vesicles', which was first published in 2014 and then in 2018 as MISEV2014 and MISEV2018, respectively. The goal of the current document, MISEV2023, is to provide researchers with an updated snapshot of available approaches and their advantages and limitations for production, separation and characterisation of EVs from multiple sources, including cell culture, body fluids and solid tissues. In addition to presenting the latest state of the art in basic principles of EV research, this document also covers advanced techniques and approaches that are currently expanding the boundaries of the field. MISEV2023 also includes new sections on EV release and uptake and a brief discussion of in vivo approaches to study EVs. Compiling feedback from ISEV expert task forces and more than 1000 researchers, this document conveys the current state of EV research to facilitate robust scientific discoveries and move the field forward even more rapidly.

Published
2024

15. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

Author

CDL extracellular vesicles, MS Nefrologie, Circulatory Health, CDL Nanomedicine, CDL Staf Research, CMM Groep Coffer, Cancer, Regenerative Medicine and Stem Cells, Zorgeenheid MKA/BT Medisch, MKA/BT Onderzoek, Experimentele Afd. Cardiologie 2, Centraal Diagnostisch Laboratorium, Experimental Cardiology Laboratory, Onderzoek Cardiovasculair Reg. Med., CDL Cluster Onderzoek en Onderwijs, Welsh, Joshua A., Goberdhan, Deborah C.I., O’Driscoll, Lorraine, Buzas, Edit I., Blenkiron, Cherie, Bussolati, Benedetta, Cai, Houjian, Di Vizio, Dolores, Driedonks, Tom A.P., Erdbrügger, Uta, Falcon-Perez, Juan M., Fu, Qing Ling, Hill, Andrew F., Lenassi, Metka, Lim, Sai Kiang, M˜y, G. Mahoney, Mohanty, Sujata, Möller, Andreas, Nieuwland, Rienk, Ochiya, Takahiro, Sahoo, Susmita, Torrecilhas, Ana C., Zheng, Lei, Zijlstra, Andries, Abuelreich, Sarah, Bagabas, Reem, Bergese, Paolo, Bridges, Esther M., Brucale, Marco, Burger, Dylan, Carney, Randy P., Cocucci, Emanuele, Crescitelli, Rossella, Hanser, Edveena, Harris, Adrian L., Haughey, Norman J., Hendrix, An, Ivanov, Alexander R., Jovanovic-Talisman, Tijana, Kruh-Garcia, Nicole A., MISEV Consortium, CDL extracellular vesicles, MS Nefrologie, Circulatory Health, CDL Nanomedicine, CDL Staf Research, CMM Groep Coffer, Cancer, Regenerative Medicine and Stem Cells, Zorgeenheid MKA/BT Medisch, MKA/BT Onderzoek, Experimentele Afd. Cardiologie 2, Centraal Diagnostisch Laboratorium, Experimental Cardiology Laboratory, Onderzoek Cardiovasculair Reg. Med., CDL Cluster Onderzoek en Onderwijs, Welsh, Joshua A., Goberdhan, Deborah C.I., O’Driscoll, Lorraine, Buzas, Edit I., Blenkiron, Cherie, Bussolati, Benedetta, Cai, Houjian, Di Vizio, Dolores, Driedonks, Tom A.P., Erdbrügger, Uta, Falcon-Perez, Juan M., Fu, Qing Ling, Hill, Andrew F., Lenassi, Metka, Lim, Sai Kiang, M˜y, G. Mahoney, Mohanty, Sujata, Möller, Andreas, Nieuwland, Rienk, Ochiya, Takahiro, Sahoo, Susmita, Torrecilhas, Ana C., Zheng, Lei, Zijlstra, Andries, Abuelreich, Sarah, Bagabas, Reem, Bergese, Paolo, Bridges, Esther M., Brucale, Marco, Burger, Dylan, Carney, Randy P., Cocucci, Emanuele, Crescitelli, Rossella, Hanser, Edveena, Harris, Adrian L., Haughey, Norman J., Hendrix, An, Ivanov, Alexander R., Jovanovic-Talisman, Tijana, Kruh-Garcia, Nicole A., and MISEV Consortium

Published
2024

16. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

Author

Celbiologie, Cell Biology, Metabolism & Cancer - Cellbiology, Welsh, Joshua A, Goberdhan, Deborah C I, O'Driscoll, Lorraine, Buzas, Edit I, Blenkiron, Cherie, Bussolati, Benedetta, Cai, Houjian, Di Vizio, Dolores, Driedonks, Tom A P, Erdbrügger, Uta, Falcon-Perez, Juan M, Fu, Qing-Ling, Hill, Andrew F, Lenassi, Metka, Lim, Sai Kiang, Mahoney, Mỹ G, Mohanty, Sujata, Möller, Andreas, Nieuwland, Rienk, Ochiya, Takahiro, Sahoo, Susmita, Torrecilhas, Ana C, Zheng, Lei, Zijlstra, Andries, Abuelreich, Sarah, Bagabas, Reem, Bergese, Paolo, Bridges, Esther M, Brucale, Marco, Burger, Dylan, Carney, Randy P, Cocucci, Emanuele, Colombo, Federico, Crescitelli, Rossella, Hanser, Edveena, Harris, Adrian L, Haughey, Norman J, Hendrix, An, Ivanov, Alexander R, Jovanovic-Talisman, Tijana, Kruh-Garcia, Nicole A, Ku'ulei-Lyn Faustino, Vroniqa, Kyburz, Diego, Lässer, Cecilia, Lennon, Kathleen M, Lötvall, Jan, Maddox, Adam L, Martens-Uzunova, Elena S, Mizenko, Rachel R, Newman, Lauren A, Ridolfi, Andrea, Rohde, Eva, Rojalin, Tatu, Rowland, Andrew, Saftics, Andras, Sandau, Ursula S, Saugstad, Julie A, Shekari, Faezeh, Swift, Simon, Ter-Ovanesyan, Dmitry, Tosar, Juan P, Useckaite, Zivile, Valle, Francesco, Varga, Zoltan, van der Pol, Edwin, van Herwijnen, Martijn J C, Wauben, Marca H M, Wehman, Ann M, Williams, Sarah, Zendrini, Andrea, Zimmerman, Alan J, Misev Consortium, Théry, Clotilde, Witwer, Kenneth W, Stoorvogel, Willem, Celbiologie, Cell Biology, Metabolism & Cancer - Cellbiology, Welsh, Joshua A, Goberdhan, Deborah C I, O'Driscoll, Lorraine, Buzas, Edit I, Blenkiron, Cherie, Bussolati, Benedetta, Cai, Houjian, Di Vizio, Dolores, Driedonks, Tom A P, Erdbrügger, Uta, Falcon-Perez, Juan M, Fu, Qing-Ling, Hill, Andrew F, Lenassi, Metka, Lim, Sai Kiang, Mahoney, Mỹ G, Mohanty, Sujata, Möller, Andreas, Nieuwland, Rienk, Ochiya, Takahiro, Sahoo, Susmita, Torrecilhas, Ana C, Zheng, Lei, Zijlstra, Andries, Abuelreich, Sarah, Bagabas, Reem, Bergese, Paolo, Bridges, Esther M, Brucale, Marco, Burger, Dylan, Carney, Randy P, Cocucci, Emanuele, Colombo, Federico, Crescitelli, Rossella, Hanser, Edveena, Harris, Adrian L, Haughey, Norman J, Hendrix, An, Ivanov, Alexander R, Jovanovic-Talisman, Tijana, Kruh-Garcia, Nicole A, Ku'ulei-Lyn Faustino, Vroniqa, Kyburz, Diego, Lässer, Cecilia, Lennon, Kathleen M, Lötvall, Jan, Maddox, Adam L, Martens-Uzunova, Elena S, Mizenko, Rachel R, Newman, Lauren A, Ridolfi, Andrea, Rohde, Eva, Rojalin, Tatu, Rowland, Andrew, Saftics, Andras, Sandau, Ursula S, Saugstad, Julie A, Shekari, Faezeh, Swift, Simon, Ter-Ovanesyan, Dmitry, Tosar, Juan P, Useckaite, Zivile, Valle, Francesco, Varga, Zoltan, van der Pol, Edwin, van Herwijnen, Martijn J C, Wauben, Marca H M, Wehman, Ann M, Williams, Sarah, Zendrini, Andrea, Zimmerman, Alan J, Misev Consortium, Théry, Clotilde, Witwer, Kenneth W, and Stoorvogel, Willem

Published
2024

17. Minimal information for studies of extracellular vesicles (MISEV2023):From basic to advanced approaches

Author

Welsh, Joshua A., Goberdhan, Deborah C.I., O’Driscoll, Lorraine, Buzas, Edit I., Blenkiron, Cherie, Bussolati, Benedetta, Cai, Houjian, Di Vizio, Dolores, Driedonks, Tom A.P., Erdbrügger, Uta, Falcon-Perez, Juan M., Fu, Qing Ling, Hill, Andrew F., Lenassi, Metka, Lim, Sai Kiang, Mahoney, M. ỹ.G., Mohanty, Sujata, Möller, Andreas, Nieuwland, Rienk, Ochiya, Takahiro, Sahoo, Susmita, Torrecilhas, Ana C., Zheng, Lei, Zijlstra, Andries, Abuelreich, Sarah, Bagabas, Reem, Bergese, Paolo, Bridges, Esther M., Brucale, Marco, Burger, Dylan, Carney, Randy P., Cocucci, Emanuele, Crescitelli, Rossella, Hanser, Edveena, Harris, Adrian L., Haughey, Norman J., Benediktsdóttir, Berglind E., Gargiulo, Ernesto, Gori, Alessandro, Guo, Wei, Hufnagel, Antonia, Di Ianni, Emilio, Jacobsen, Soren, Li, Bo, Mellergaard, Maiken, Nejsum, Peter, Nolan, John P., Østergaard, Ole, Yarani, Reza, Yin, Hang, Welsh, Joshua A., Goberdhan, Deborah C.I., O’Driscoll, Lorraine, Buzas, Edit I., Blenkiron, Cherie, Bussolati, Benedetta, Cai, Houjian, Di Vizio, Dolores, Driedonks, Tom A.P., Erdbrügger, Uta, Falcon-Perez, Juan M., Fu, Qing Ling, Hill, Andrew F., Lenassi, Metka, Lim, Sai Kiang, Mahoney, M. ỹ.G., Mohanty, Sujata, Möller, Andreas, Nieuwland, Rienk, Ochiya, Takahiro, Sahoo, Susmita, Torrecilhas, Ana C., Zheng, Lei, Zijlstra, Andries, Abuelreich, Sarah, Bagabas, Reem, Bergese, Paolo, Bridges, Esther M., Brucale, Marco, Burger, Dylan, Carney, Randy P., Cocucci, Emanuele, Crescitelli, Rossella, Hanser, Edveena, Harris, Adrian L., Haughey, Norman J., Benediktsdóttir, Berglind E., Gargiulo, Ernesto, Gori, Alessandro, Guo, Wei, Hufnagel, Antonia, Di Ianni, Emilio, Jacobsen, Soren, Li, Bo, Mellergaard, Maiken, Nejsum, Peter, Nolan, John P., Østergaard, Ole, Yarani, Reza, and Yin, Hang

Abstract

Extracellular vesicles (EVs), through their complex cargo, can reflect the state of their cell of origin and change the functions and phenotypes of other cells. These features indicate strong biomarker and therapeutic potential and have generated broad interest, as evidenced by the steady year-on-year increase in the numbers of scientific publications about EVs. Important advances have been made in EV metrology and in understanding and applying EV biology. However, hurdles remain to realising the potential of EVs in domains ranging from basic biology to clinical applications due to challenges in EV nomenclature, separation from non-vesicular extracellular particles, characterisation and functional studies. To address the challenges and opportunities in this rapidly evolving field, the International Society for Extracellular Vesicles (ISEV) updates its ‘Minimal Information for Studies of Extracellular Vesicles’, which was first published in 2014 and then in 2018 as MISEV2014 and MISEV2018, respectively. The goal of the current document, MISEV2023, is to provide researchers with an updated snapshot of available approaches and their advantages and limitations for production, separation and characterisation of EVs from multiple sources, including cell culture, body fluids and solid tissues. In addition to presenting the latest state of the art in basic principles of EV research, this document also covers advanced techniques and approaches that are currently expanding the boundaries of the field. MISEV2023 also includes new sections on EV release and uptake and a brief discussion of in vivo approaches to study EVs. Compiling feedback from ISEV expert task forces and more than 1000 researchers, this document conveys the current state of EV research to facilitate robust scientific discoveries and move the field forward even more rapidly., Extracellular vesicles (EVs), through their complex cargo, can reflect the state of their cell of origin and change the functions and phenotypes of other cells. These features indicate strong biomarker and therapeutic potential and have generated broad interest, as evidenced by the steady year-on-year increase in the numbers of scientific publications about EVs. Important advances have been made in EV metrology and in understanding and applying EV biology. However, hurdles remain to realising the potential of EVs in domains ranging from basic biology to clinical applications due to challenges in EV nomenclature, separation from non-vesicular extracellular particles, characterisation and functional studies. To address the challenges and opportunities in this rapidly evolving field, the International Society for Extracellular Vesicles (ISEV) updates its ‘Minimal Information for Studies of Extracellular Vesicles’, which was first published in 2014 and then in 2018 as MISEV2014 and MISEV2018, respectively. The goal of the current document, MISEV2023, is to provide researchers with an updated snapshot of available approaches and their advantages and limitations for production, separation and characterisation of EVs from multiple sources, including cell culture, body fluids and solid tissues. In addition to presenting the latest state of the art in basic principles of EV research, this document also covers advanced techniques and approaches that are currently expanding the boundaries of the field. MISEV2023 also includes new sections on EV release and uptake and a brief discussion of in vivo approaches to study EVs. Compiling feedback from ISEV expert task forces and more than 1000 researchers, this document conveys the current state of EV research to facilitate robust scientific discoveries and move the field forward even more rapidly.

Published
2024

18. Within-Subject Variability and the Influence of Exercise Training History on the Resting Plasma Metabolome in Men.

Author

Darragh, Ian A. J., O'Driscoll, Lorraine, and Egan, Brendan

Subjects
*STATISTICS, *RELIABILITY (Personality trait), *BLOOD plasma, *FOOD consumption, *LIQUID chromatography, *EXERCISE physiology, *ATHLETES, *RELAXATION for health, *COMPARATIVE studies, *EXERCISE, *RESEARCH funding, *ENDURANCE sports, *MASS spectrometry, *INTRACLASS correlation, *FACTOR analysis, *DESCRIPTIVE statistics, *METABOLITES
Abstract

This study investigated within-subject variability in the circulating metabolome under controlled conditions, and whether divergent exercise training backgrounds were associated with alterations in the circulating metabolome assessed in resting samples. Thirty-seven men comprising of endurance athletes (END; body mass, 71.0 ± 6.8 kg; fat-free mass index, 16.9 ± 1.1 kg/m²), strength athletes (STR; 94.5 ± 8.8 kg; 23.0 ± 1.8 kg/m²), and recreationally active controls (CON; 77.6 ± 7.7 kg; 18.1 ± 1.0 kg/m²) provided blood samples after an overnight fast on two separate occasions controlled for time of day of sampling, recent dietary intake, time since last meal, and time since last exercise training session. A targeted profile of metabolites, performed using liquid chromatography and mass spectrometry on plasma samples, identified 166 individual metabolites and metabolite features, which were analyzed with intraclass correlation coefficients, a multilevel principal component analysis, and univariate t tests adjusted for multiple comparisons. The median intraclass correlation coefficient was .49, with 46 metabolites displaying good reliability and 31 metabolites displaying excellent reliability. No difference in the abundance of any individual metabolite was identified within groups when compared between visits, but a combined total of 44 metabolites were significantly different (false discovery rate <0.05) between groups (END vs. CON, 42 metabolites; STR vs. CON, 10 metabolites; and END vs. STR, five metabolites). Under similar measurement conditions, the reliability of resting plasma metabolite concentrations varies largely at the level of individual metabolites with ~48% of metabolites displaying good-to-excellent reliability. However, a history of exercise training was associated with alterations in the abundance of ~28% of metabolites in the targeted profile employed in this study. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

19. Functional assays reflective of cancer hallmarks in BT‐549 cells are not impacted by media supplemented with exercise‐trained plasma.

Author

Darragh, Ian A. J., Martinez‐Pacheco, Sarai, O'Driscoll, Lorraine, and Egan, Brendan

Subjects
EXTRACELLULAR matrix, CELL migration, EXERCISE physiology, ENDURANCE athletes, SERUM-free culture media, ANOIKIS, OLDER men
Abstract

Media supplemented with sera from acutely exercised men has been shown to have 'anti‐cancer' effects on prostate and breast cancer cell lines. This study investigated whether media supplemented with plasma samples taken at rest (≥30 h since the most recent exercise session) from men who were endurance‐trained (END), strength‐trained (STR) or recreationally active controls (CON) impacted the results of four assays that mimic hallmarks of cancer (proliferation, migration, extracellular matrix invasion and anoikis resistance) in the BT‐549 breast cancer cell line. Compared to control conditions of either serum‐free media or fetal bovine serum as appropriate, BT‐549 cells cultured with plasma‐supplemented media regardless of group resulted in greater cell proliferation (∼20–50%) and cell migration (∼15–20%), and lower extracellular matrix invasion (∼10–20%) and anoikis resistance (∼15–20%). Supplementing media with plasma from END or STR did not impact any outcomes of these assays compared to plasma from CON. Media supplemented with human plasma can impact functional assays reflective of cancer hallmarks in BT‐549 cells, but effects of exercise on proliferation, migration, extracellular matrix invasion and anoikis resistance were not evident in resting blood samples of individuals with a prior history of exercise training. What is the central question of this study?Little is known regarding the effects of media supplemented with resting plasma from exercise‐trained individuals, despite the established bioactive effects of acutely exercised samples. Does media supplemented with resting plasma from endurance‐trained, strength‐trained or recreationally active controls impact hallmarks of cancer in BT‐549 cells?What is the main finding and its importance?Supplementing media with plasma from these trained athletes did not impact proliferation, migration, invasion or anoikis resistance compared to plasma from recreationally‐active controls. These findings suggest that 'anti‐cancer' effects of exercise are not present in resting blood samples of exercise‐trained individuals. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. MIBlood‐EV: Minimal information to enhance the quality and reproducibility of blood extracellular vesicle research

Author

Lucien, Fabrice, primary, Gustafson, Dakota, additional, Lenassi, Metka, additional, Li, Bo, additional, Teske, Jacob J., additional, Boilard, Eric, additional, von Hohenberg, Katharina Clemm, additional, Falcón‐Perez, Juan Manual, additional, Gualerzi, Alice, additional, Reale, Antonia, additional, Jones, Jennifer C., additional, Lässer, Cecilia, additional, Lawson, Charlotte, additional, Nazarenko, Irina, additional, O'Driscoll, Lorraine, additional, Pink, Ryan, additional, Siljander, Pia R‐M, additional, Soekmadji, Carolina, additional, Hendrix, An, additional, Welsh, Joshua A, additional, Witwer, Kenneth W., additional, and Nieuwland, Rienk, additional

Published
2023
Full Text
View/download PDF

26. Cell culture‐derived extracellular vesicles: Considerations for reporting cell culturing parameters

Author

Shekari, Faezeh, primary, Alibhai, Faisal J., additional, Baharvand, Hossein, additional, Börger, Verena, additional, Bruno, Stefania, additional, Davies, Owen, additional, Giebel, Bernd, additional, Gimona, Mario, additional, Salekdeh, Ghasem Hosseini, additional, Martin‐Jaular, Lorena, additional, Mathivanan, Suresh, additional, Nelissen, Inge, additional, Nolte‐’t Hoen, Esther, additional, O'Driscoll, Lorraine, additional, Perut, Francesca, additional, Pluchino, Stefano, additional, Pocsfalvi, Gabriella, additional, Salomon, Carlos, additional, Soekmadji, Carolina, additional, Staubach, Simon, additional, Torrecilhas, Ana Claudia, additional, Shelke, Ganesh Vilas, additional, Tertel, Tobias, additional, Zhu, Dandan, additional, Théry, Clotilde, additional, Witwer, Kenneth, additional, and Nieuwland, Rienk, additional

Published
2023
Full Text
View/download PDF

30. MISEV2023: An updated guide to EV research and applications.

Author

Welsh, Joshua A., Goberdhan, Deborah C., O'Driscoll, Lorraine, Théry, Clotilde, and Witwer, Kenneth W.

Subjects
EXTRACELLULAR vesicles, LITERATURE reviews
Abstract

The article "MISEV2023: An updated guide to EV research and applications" is a comprehensive guide to the study of extracellular vesicles (EVs). It covers various aspects of EV research, including terminology, collection and processing, characterization, and studying EVs in vivo. The guide was developed through a survey and input from the International Society for Extracellular Vesicles (ISEV) board, with contributions from 74 scientists and 1051 co-authors from 53 countries. While not a comprehensive review, the guide includes over 500 citations suggested by experts and the community. The authors acknowledge the limitations of the guide and invite critique and collaboration to improve future versions. [Extracted from the article]

Published
2024
Full Text
View/download PDF

31. Suppl Fig. S1 from Neuromedin U: A Candidate Biomarker and Therapeutic Target to Predict and Overcome Resistance to HER-Tyrosine Kinase Inhibitors

Author

Rani, Sweta, primary, Corcoran, Claire, primary, Shiels, Liam, primary, Germano, Serena, primary, Breslin, Susan, primary, Madden, Stephen, primary, McDermott, Martina S., primary, Browne, Brigid C., primary, O'Donovan, Norma, primary, Crown, John, primary, Gogarty, Martina, primary, Byrne, Annette T., primary, and O'Driscoll, Lorraine, primary

Published
2023
Full Text
View/download PDF

32. Data from Neuromedin U: A Candidate Biomarker and Therapeutic Target to Predict and Overcome Resistance to HER-Tyrosine Kinase Inhibitors

Author

Rani, Sweta, primary, Corcoran, Claire, primary, Shiels, Liam, primary, Germano, Serena, primary, Breslin, Susan, primary, Madden, Stephen, primary, McDermott, Martina S., primary, Browne, Brigid C., primary, O'Donovan, Norma, primary, Crown, John, primary, Gogarty, Martina, primary, Byrne, Annette T., primary, and O'Driscoll, Lorraine, primary

Published
2023
Full Text
View/download PDF

33. Suppl Table 2 from Neuromedin U: A Candidate Biomarker and Therapeutic Target to Predict and Overcome Resistance to HER-Tyrosine Kinase Inhibitors

Author

Rani, Sweta, primary, Corcoran, Claire, primary, Shiels, Liam, primary, Germano, Serena, primary, Breslin, Susan, primary, Madden, Stephen, primary, McDermott, Martina S., primary, Browne, Brigid C., primary, O'Donovan, Norma, primary, Crown, John, primary, Gogarty, Martina, primary, Byrne, Annette T., primary, and O'Driscoll, Lorraine, primary

Published
2023
Full Text
View/download PDF

34. Suppl Material & Suppl. Table S1 from Neuromedin U: A Candidate Biomarker and Therapeutic Target to Predict and Overcome Resistance to HER-Tyrosine Kinase Inhibitors

Author

Rani, Sweta, primary, Corcoran, Claire, primary, Shiels, Liam, primary, Germano, Serena, primary, Breslin, Susan, primary, Madden, Stephen, primary, McDermott, Martina S., primary, Browne, Brigid C., primary, O'Donovan, Norma, primary, Crown, John, primary, Gogarty, Martina, primary, Byrne, Annette T., primary, and O'Driscoll, Lorraine, primary

Published
2023
Full Text
View/download PDF

35. MIBlood-EV : minimal information to enhance the quality and reproducibility of blood extracellular vesicle research

Author

Lucien, Fabrice, Gustafson, Dakota, Lenassi, Metka, Li Bo, Teske, Jacob J., Boilard, Eric, von Hohenberg, Katharina Clemm, Falcón-Perez, Juan Manual, Gualerzi, Alice, Reale, Antonia, Jones, Jennifer C., Lässer, Cecilia, Lawson, Charlotte, Nazarenko, Irinia, O'Driscoll, Lorraine, Pink, Ryan, Siljander, Pia R-M, Soekmadji, Carolina, Hendrix, An, Welsh, Joshua A., Witwer, Kenneth W., Nieuwland, Rienk, Lucien, Fabrice, Gustafson, Dakota, Lenassi, Metka, Li Bo, Teske, Jacob J., Boilard, Eric, von Hohenberg, Katharina Clemm, Falcón-Perez, Juan Manual, Gualerzi, Alice, Reale, Antonia, Jones, Jennifer C., Lässer, Cecilia, Lawson, Charlotte, Nazarenko, Irinia, O'Driscoll, Lorraine, Pink, Ryan, Siljander, Pia R-M, Soekmadji, Carolina, Hendrix, An, Welsh, Joshua A., Witwer, Kenneth W., and Nieuwland, Rienk

Abstract

Blood is the most commonly used body fluid for extracellular vesicle (EV) research. The composition of a blood sample and its derivatives (i.e., plasma and serum) are not only donor-dependent but also influenced by collection and preparation protocols. Since there are hundreds of pre-analytical protocols and over forty variables, the development of standard operating procedures for EV research is very challenging. To improve the reproducibility of blood EV research, the International Society for Extracellular Vesicles (ISEV) Blood EV Task Force proposes standardized reporting of (i) the applied blood collection and preparation protocol and (ii) the quality of the prepared plasma and serum samples. Gathering detailed information will provide insight into the performance of the protocols and more effectively identify potential confounders in the prepared plasma and serum samples. To collect this information, the ISEV Blood EV Task Force created the Minimal Information for Blood EV research (MIBlood-EV), a tool to record and report information about pre-analytical protocols used for plasma and serum preparation as well as assays used to assess the quality of these preparations. This tool does not require modifications of established local pre-analytical protocols and can be easily implemented to enhance existing databases thereby enabling evidence-based optimization of pre-analytical protocols through meta-analysis. Taken together, insight into the quality of prepared plasma and serum samples will (i) improve the quality of biobanks for EV research, (ii) guide the exchange of plasma and serum samples between biobanks and laboratories, (iii) facilitate inter-laboratory comparative EV studies, and (iv) improve the peer review process.

Published
2023

39. Dairy proteins, dairy lipids, and postprandial lipemia in persons with abdominal obesity (DairyHealth): a 12-wk, randomized, parallel-controlled, double-blinded, diet intervention study

Author

Bohl, Mette, Bjørnshave, Ann, Rasmussen, Kia V, Schioldan, Anne Grethe, Amer, Bashar, Larsen, Mette K, Dalsgaard, Trine K, Holst, Jens J, Herrmann, Annkatrin, O’Neill, Sadhbh, O’Driscoll, Lorraine, Afman, Lydia, Jensen, Erik, Christensen, Merete M, Gregersen, Søren, and Hermansen, Kjeld

Published
2015
Full Text
View/download PDF

41. Perinatal derivatives: How to best validate their immunomodulatory functions

Author

Papait, Andrea, primary, Silini, Antonietta Rosa, additional, Gazouli, Maria, additional, Malvicini, Ricardo, additional, Muraca, Maurizio, additional, O’Driscoll, Lorraine, additional, Pacienza, Natalia, additional, Toh, Wei Seong, additional, Yannarelli, Gustavo, additional, Ponsaerts, Peter, additional, Parolini, Ornella, additional, Eissner, Günther, additional, Pozzobon, Michela, additional, Lim, Sai Kiang, additional, and Giebel, Bernd, additional

Published
2022
Full Text
View/download PDF

44. Perinatal derivatives: How to best validate their immunomodulatory functions

Author

Papait, Andrea, Silini, Antonietta Rosa, Gazouli, Maria, Malvicini, Ricardo, Muraca, Maurizio, O'Driscoll, Lorraine, Pacienza, Natalia, Toh, Wei Seong, Yannarelli, Gustavo, Ponsaerts, Peter, Parolini, Ornella, Eissner, Günther, Pozzobon, Michela, Lim, Sai Kiang, Giebel, Bernd, Papait, Andrea (ORCID:0000-0003-1229-9671), Parolini, Ornella (ORCID:0000-0002-5211-6430), Papait, Andrea, Silini, Antonietta Rosa, Gazouli, Maria, Malvicini, Ricardo, Muraca, Maurizio, O'Driscoll, Lorraine, Pacienza, Natalia, Toh, Wei Seong, Yannarelli, Gustavo, Ponsaerts, Peter, Parolini, Ornella, Eissner, Günther, Pozzobon, Michela, Lim, Sai Kiang, Giebel, Bernd, Papait, Andrea (ORCID:0000-0003-1229-9671), and Parolini, Ornella (ORCID:0000-0002-5211-6430)

Abstract

Perinatal tissues, mainly the placenta and umbilical cord, contain a variety of different somatic stem and progenitor cell types, including those of the hematopoietic system, multipotent mesenchymal stromal cells (MSCs), epithelial cells and amnion epithelial cells. Several of these perinatal derivatives (PnDs), as well as their secreted products, have been reported to exert immunomodulatory therapeutic and regenerative functions in a variety of pre-clinical disease models. Following experience with MSCs and their extracellular vesicle (EV) products, successful clinical translation of PnDs will require robust functional assays that are predictive for the relevant therapeutic potency. Using the examples of T cell and monocyte/macrophage assays, we here discuss several assay relevant parameters for assessing the immunomodulatory activities of PnDs. Furthermore, we highlight the need to correlate the in vitro assay results with preclinical or clinical outcomes in order to ensure valid predictions about the in vivo potency of therapeutic PnD cells/products in individual disease settings.

Published
2022

50. Updating MISEV: Evolving the minimal requirements for studies of extracellular vesicles

Author

Witwer, Kenneth W, primary, Goberdhan, Deborah CI, additional, O'Driscoll, Lorraine, additional, Théry, Clotilde, additional, Welsh, Joshua A, additional, Blenkiron, Cherie, additional, Buzás, Edit I, additional, Di Vizio, Dolores, additional, Erdbrügger, Uta, additional, Falcón‐Pérez, Juan M, additional, Fu, Qing‐Ling, additional, Hill, Andrew F, additional, Lenassi, Metka, additional, Lötvall, Jan, additional, Nieuwland, Rienk, additional, Ochiya, Takahiro, additional, Rome, Sophie, additional, Sahoo, Susmita, additional, and Zheng, Lei, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results